Valeant: Is the Rally Over?

Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that reassure investor that it was making progresses rebuilding itself after following a series of investigations into the drug maker’s accounting and pricing practices. Also helping fuel the upswing, Valeant reduced its total debt by $6 billion since the […]